Melina Peressini
A5092083225- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Cancer therapeutics and mechanisms
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Advanced biosensing and bioanalysis techniques
- Lung Cancer Diagnosis and Treatment
- RNA modifications and cancer
- Advanced Biosensing Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastric Cancer Management and Outcomes
- Melanoma and MAPK Pathways
Research Institute Hospital 12 de Octubre
2023-2024
Hospital Universitario 12 De Octubre
2023
Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and identify biomarkers of long-term chemoimmunotherapy benefit human ES-SCLC.
<p>Supplementary Figures</p>
<p>Supplementary File</p>
<p>Supplementary File</p>
<div>AbstractPurpose:<p>Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and identify biomarkers of long-term chemoimmunotherapy benefit human ES-SCLC.</p>Experimental Design:<p>We analyzed tumor samples from 58 patients with ES-SCLC enrolled two multicenter single-arm phase IIIb studies evaluating frontline Spain:...
<div>AbstractPurpose:<p>Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and identify biomarkers of long-term chemoimmunotherapy benefit human ES-SCLC.</p>Experimental Design:<p>We analyzed tumor samples from 58 patients with ES-SCLC enrolled two multicenter single-arm phase IIIb studies evaluating frontline Spain:...
<p>Supplementary Figures</p>
To study programmed death ligand 1 (PD-L1) expression and tumour infiltrating lymphocytes (TILs) in patients with early-stage non-small cell lung carcinoma (NSCLC) artificial intelligence (AI) algorithms.
8594 Background: Transcriptomic subtyping holds promise for personalized therapy in SCLC, but intratumoral transcriptomic heterogeneity and its clinical significance remain poorly defined. In this study, we aimed to assess transcription factor defined subtypes within multiple regions of intact tissues identify gen sets associated with long-term chemo-immunotherapy benefit. Methods: We assessed baseline FFPE tumors from 32 ES-SCLC patients enrolled the IMfirst trial (EudraCT: 2019-002784-10)....
Transcriptomic subtyping holds promise for personalized therapy in SCLC, but intratumoral transcriptomic heterogeneity and its clinical significance remain poorly defined. In this study, we aimed to assess transcription factor-defined subtypes within multiple regions of intact tissues identify gene sets associated with long-term chemoimmunotherapy benefit. We assessed baseline FFPE tumors from 26 ES-SCLC patients enrolled the CANTABRICO trial (EudraCT: 2020-002328-35). used GeoMxTM DSP...